Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Harvard Business School
AstraZeneca
Express Scripts
Mallinckrodt

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for TH-302

See Plans and Pricing

« Back to Dashboard

What is the drug development status for TH-302?

TH-302 is an investigational drug.

There have been 24 clinical trials for TH-302. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2011.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Sarcoma, and Adenocarcinoma. The leading clinical trial sponsors are Threshold Pharmaceuticals, Merck KGaA, and EMD Serono.

There are nine US patents protecting this investigational drug and sixty-eight international patents.

Recent Clinical Trials for TH-302
TitleSponsorPhase
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.Threshold PharmaceuticalsPhase 1
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.Zuyderland Medical CentrePhase 1
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.Maastricht Radiation OncologyPhase 1

See all TH-302 clinical trials

Clinical Trial Summary for TH-302

Top disease conditions for TH-302
Top clinical trial sponsors for TH-302

See all TH-302 clinical trials

US Patents for TH-302

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TH-302   Start Trial Predictive biomarker for hypoxia-activated prodrug therapy Molecular Templates, Inc. (Austin, TX)   Start Trial
TH-302   Start Trial Phosphoramidate alkylator prodrugs Threshold Pharmaceuticals, Inc. (Redwood CIty, CA)   Start Trial
TH-302   Start Trial Phosphoramidate alkylator prodrugs Threshold Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
TH-302   Start Trial Phosphoramidate alkylator prodrugs for the treatment of cancer Threshold Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
TH-302   Start Trial Phosphoramidate alkylator prodrugs Threshold Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
TH-302   Start Trial Treatment of cancer using hypoxia activated prodrugs Threshold Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TH-302

Drugname Country Document Number Estimated Expiration Related US Patent
TH-302 World Intellectual Property Organization (WIPO) 2015069489 2033-11-06   Start Trial
TH-302 Australia 2006263433 2025-06-29   Start Trial
TH-302 Australia 2011202075 2025-06-29   Start Trial
TH-302 Brazil PI0612845 2025-06-29   Start Trial
TH-302 Canada 2613312 2025-06-29   Start Trial
TH-302 China 101501054 2025-06-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
AstraZeneca
Moodys
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.